Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2011, Article ID 475983, 17 pages
http://dx.doi.org/10.1155/2011/475983
Review Article

Potential Markers for Detection and Monitoring of Ovarian Cancer

1Center for Reproductive Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
2Laboratory for Molecular Reproduction and Genetics, Department of Anatomy, All India Institute of Medical Sciences, New Delhi 110029, India

Received 16 September 2010; Accepted 8 February 2011

Academic Editor: Nelson N. H. Teng

Copyright © 2011 Brandon J. D. Rein et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Banks, “The epidemiology of ovarian cancer,” in Ovarian Cancer: Methods and Protocols, J. M. S. Bartlett, Ed., Humana Press, Totowa, NJ, USA, 2000. View at Google Scholar
  2. “United States Cancer Statistics 2002 Incidence and Mortality,” 2005, http://seer.cancer.gov/csr/1975_2006/results_single/sect_01_table.01.pdf.
  3. N. Urban and C. Drescher, “Potential and limitations in early diagnosis of ovarian cancer,” in Ovarian Cancer: State of the Art and Future Directions in Translational Research, G. Coukos, A. Berchuck, and R. Ozols, Eds., pp. 3–14, Springer, New York, NY, USA, 2008. View at Google Scholar
  4. D. Badgwell and R. C. Bast, “Early detection of ovarian cancer,” Disease Markers, vol. 23, no. 5-6, pp. 397–410, 2007. View at Google Scholar · View at Scopus
  5. P. Hartge, A. S. Whittemore, J. Itnyre, L. McGowan, and D. Cramer, “Rates and risks of ovarian cancer in subgroups of white women in the United States,” Obstetrics and Gynecology, vol. 84, no. 5, pp. 760–764, 1994. View at Google Scholar · View at Scopus
  6. A. S. Whittemore, R. Harris, J. Itnyre et al., “Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women,” American Journal of Epidemiology, vol. 136, no. 10, pp. 1184–1203, 1992. View at Google Scholar · View at Scopus
  7. A. S. Whittemore, “Characteristics relating to ovarian cancer risk: implications for prevention and detection,” Gynecologic Oncology, vol. 55, no. 3, pp. S15–S19, 1994. View at Publisher · View at Google Scholar · View at Scopus
  8. V. Beral, P. Fraser, and C. Chilvers, “Does pregnancy protect against ovarian cancer?” Lancet, vol. 1, no. 8073, pp. 1083–1087, 1978. View at Google Scholar · View at Scopus
  9. G. Mor, I. Visintin, Y. Lai et al., “Serum protein markers for early detection of ovarian cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 21, pp. 7677–7682, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. I. J. Jacobs, S. J. Skates, N. MacDonald et al., “Screening for ovarian cancer: a pilot randomised controlled trial,” Lancet, vol. 353, no. 9160, pp. 1207–1210, 1999. View at Publisher · View at Google Scholar · View at Scopus
  11. S. J. Skates, I. J. Jacobs, and R. C. Knapp, “Tumor markers in screening for ovarian cancer,” in Ovarian Cancer: Methods and Protocols, J. M. S. Bartlett, Ed., pp. 61–73, Humana Press, Totowa, NJ, USA, 2000. View at Google Scholar
  12. D. Gupta and C. G. Lis, “Role of CA125 in predicting ovarian cancer survival—a review of the epidemiological literature,” Journal of Ovarian Research, vol. 2, no. 1, article no. 13, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Nakae, I. Iwamoto, T. Fujino et al., “Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer,” Journal of Obstetrics and Gynaecology Research, vol. 32, no. 3, pp. 309–314, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. K. J. Helzlsouer, T. L. Bush, A. J. Alberg, K. M. Bass, H. Zacur, and G. W. Comstock, “Prospective study of serum CA-125 levels as markers of ovarian cancer,” Journal of the American Medical Association, vol. 269, no. 9, pp. 1123–1126, 1993. View at Publisher · View at Google Scholar · View at Scopus
  15. U. Menon, A. Gentry-Maharaj, R. Hallett et al., “Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS),” The Lancet Oncology, vol. 10, no. 4, pp. 327–340, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. V. Kumar, N. Fausto, and A. Abbas, Robbins & Cotran Pathologic Basis of Disease, Saunders, Philadelphia, Pa, USA, 7th edition, 2005.
  17. C. B. Wilcox, B. E. Baysal, H. H. Gallion, M. A. Strange, and J. A. DeLoia, “High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors,” Cancer Genetics and Cytogenetics, vol. 159, no. 2, pp. 114–122, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. J. R. Van Nagell Jr., P. D. DePriest, F. R. Ueland et al., “Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened,” Cancer, vol. 109, no. 9, pp. 1887–1896, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. T. H. Bourne, S. Campbell, K. M. Reynolds et al., “Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging,” British Medical Journal, vol. 306, no. 6884, pp. 1025–1029, 1993. View at Google Scholar · View at Scopus
  20. S. Sato, Y. Yokoyama, T. Sakamoto, M. Futagami, and Y. Saito, “Usefulness of mass screening for ovarian carcinoma using transvaginal ultrasonography,” Cancer, vol. 89, no. 3, pp. 582–588, 2000. View at Publisher · View at Google Scholar · View at Scopus
  21. N. S. Holalkere, A. M. Katur, and S. I. Lee, “Issues in imaging malignant neoplasms of the female reproductive system,” Current Problems in Diagnostic Radiology, vol. 38, no. 1, pp. 1–16, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. N. Urban and C. Drescher, “Current and future developments in screening for ovarian cancer,” Women's Health, vol. 2, no. 5, pp. 733–742, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. R. C. Bast Jr., N. Urban, V. Shridhar et al., “Early detection of ovarian cancer: promise and reality,” Cancer Treatment and Research, vol. 107, pp. 61–97, 2002. View at Google Scholar · View at Scopus
  24. C. A. Barton, S. J. Clark, N. F. Hacker, and P. M. O'Brien, “Epigenetic markers of ovarian cancer,” Advances in Experimental Medicine and Biology, vol. 622, pp. 35–51, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Zhao, L. Annamalai, C. Guo et al., “Circulating haptoglobin is an independent prognostic factor in the sera of patients with epithelial ovarian cancer,” Neoplasia, vol. 9, no. 1, pp. 1–7, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. N. Ahmed, K. T. Oliva, G. Barker et al., “Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer,” Proteomics, vol. 5, no. 17, pp. 4625–4636, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. LI. H. Bao, H. Sakaguchi, J. Fujimoto, and T. Tamaya, “Osteopontin in metastatic lesions as a prognostic marker in ovarian cancers,” Journal of Biomedical Science, vol. 14, no. 3, pp. 373–381, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. R. G. Moore, A. K. Brown, M. C. Miller et al., “The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass,” Gynecologic Oncology, vol. 108, no. 2, pp. 402–408, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. N. Scholler, M. Crawford, A. Sato et al., “Bead-based ELISA for validation of ovarian cancer early detection markers,” Clinical Cancer Research, vol. 12, no. 7, pp. 2117–2124, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Hassan, A. T. Remaley, M. L. Sampson et al., “Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer,” Clinical Cancer Research, vol. 12, no. 2, pp. 447–453, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. M. W. McIntosh, C. Drescher, B. Karlan et al., “Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma,” Gynecologic Oncology, vol. 95, no. 1, pp. 9–15, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. N. Scholler, N. Fu, YI. Yang et al., “Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 20, pp. 11531–11536, 1999. View at Publisher · View at Google Scholar · View at Scopus
  33. I. Simon, S. Zhuo, L. Corral et al., “B7-H4 Is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer,” Cancer Research, vol. 66, no. 3, pp. 1570–1575, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. I. Simon, D. Katsaros, I. Rigault de la Longrais et al., “B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression,” Gynecologic Oncology, vol. 106, no. 2, pp. 334–341, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. F. P. Costa, E. L. Batista Junior, A. Zelmanowicz et al., “Prostasin, a potential tumor marker in ovarian cancer—a pilot study,” Clinics, vol. 64, no. 7, pp. 641–644, 2009. View at Publisher · View at Google Scholar
  36. S. C. Mok, J. Chao, S. Skates et al., “Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology,” Journal of the National Cancer Institute, vol. 93, no. 19, pp. 1458–1464, 2001. View at Google Scholar · View at Scopus
  37. F. J. Xu, S. Ramakrishnan, L. Daly et al., “Increased serum levels of macrophage colony-stimulating factor in ovarian cancer,” American Journal of Obstetrics and Gynecology, vol. 165, no. 5, pp. 1356–1362, 1991. View at Google Scholar · View at Scopus
  38. M. Suzuki, M. Ohwada, I. Aida, T. Tamada, T. Hanamura, and M. Nagatomo, “Macrophage colony-stimulating factor as a tumor marker for epithelial ovarian cancer,” Obstetrics and Gynecology, vol. 82, no. 6, pp. 946–950, 1993. View at Google Scholar · View at Scopus
  39. L. Li, L. Wang, W. Zhang et al., “Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer,” Anticancer Research, vol. 24, no. 3B, pp. 1973–1979, 2004. View at Google Scholar · View at Scopus
  40. B. C. Cooper, J. M. Ritchie, C. L. W. Broghammer et al., “Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer,” Clinical Cancer Research, vol. 8, no. 10, pp. 3193–3197, 2002. View at Google Scholar · View at Scopus
  41. A. E. Lokshin, M. Winans, D. Landsittel et al., “Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer,” Gynecologic Oncology, vol. 102, no. 2, pp. 244–251, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. E. Gorelik, D. P. Landsittel, A. M. Marrangoni et al., “Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer,” Cancer Epidemiology Biomarkers and Prevention, vol. 14, no. 4, pp. 981–987, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. B. Ye, S. Skates, S. C. Mok et al., “Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine,” Clinical Cancer Research, vol. 12, no. 2, pp. 432–441, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. C. Van Haaften-Day, YU. Shen, F. Xu et al., “OVXL, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal,” Cancer, vol. 92, no. 11, pp. 2837–2844, 2001. View at Publisher · View at Google Scholar · View at Scopus
  45. R. Sutphen, Y. Xu, G. D. Wilbanks et al., “Lysophospholipids are potential biomarkers of ovarian cancer,” Cancer Epidemiology Biomarkers and Prevention, vol. 13, no. 7, pp. 1185–1191, 2004. View at Google Scholar · View at Scopus
  46. L. E. Moore, E. T. Fung, M. McGuire et al., “Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population,” Cancer Epidemiology Biomarkers and Prevention, vol. 15, no. 9, pp. 1641–1646, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. R. L. Baldwin, E. Nemeth, H. Tran et al., “BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study,” Cancer Research, vol. 60, no. 19, pp. 5329–5333, 2000. View at Google Scholar · View at Scopus
  48. Y. Yu, F. Xu, H. Peng et al., “NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 1, pp. 214–219, 1999. View at Publisher · View at Google Scholar · View at Scopus
  49. G. C. Sellar, K. P. Watt, G. J. Rabiasz et al., “OPCML at 11q25 is epigenetically inactivated and has tumor- suppressor function in epithelial ovarian cancer,” Nature Genetics, vol. 34, no. 3, pp. 337–343, 2003. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Gupta, A. K. Godwin, L. Vanderveer, A. Lu, and J. Liu, “Hypomethylation of the Synuclein γ gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma,” Cancer Research, vol. 63, no. 3, pp. 664–673, 2003. View at Google Scholar · View at Scopus
  51. A. Czekierdowski, S. Czekierdowska, M. Wielgos, A. Smolen, P. Kaminski, and J. Kotarski, “The role of CpG islands hypomethylation and abnormal expression of neuronal protein synuclein-γ (SNCG) in ovarian cancer,” Neuroendocrinology Letters, vol. 27, no. 3, pp. 381–386, 2006. View at Google Scholar · View at Scopus
  52. M. Widschwendter, G. Jiang, C. Woods et al., “DNA hypomethylation and ovarian cancer biology,” Cancer Research, vol. 64, no. 13, pp. 4472–4480, 2004. View at Publisher · View at Google Scholar · View at Scopus
  53. I. I. De Caceres, C. Battagli, M. Esteller et al., “Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients,” Cancer Research, vol. 64, no. 18, pp. 6476–6481, 2004. View at Publisher · View at Google Scholar · View at Scopus
  54. A. Wiley, D. Katsaros, S. Fracchioli, and H. Yu, “Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer,” International Journal of Gynecological Cancer, vol. 16, no. 1, pp. 210–218, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Kaneuchi, M. Sasaki, Y. Tanaka et al., “Expression and methylation status of 14-3-3 sigma gene can characterize the different histological features of ovarian cancer,” Biochemical and Biophysical Research Communications, vol. 316, no. 4, pp. 1156–1162, 2004. View at Publisher · View at Google Scholar · View at Scopus
  56. G. Strathdee, J. K. Vass, K. A. Oien, N. Siddiqui, J. Curto-Garcia, and R. Brown, “Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy,” Gynecologic Oncology, vol. 97, no. 3, pp. 898–903, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. M. Fujita, T. Enomoto, M. Inoue et al., “Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary,” Japanese Journal of Cancer Research, vol. 85, no. 12, pp. 1247–1256, 1994. View at Google Scholar
  58. K. C. Wiegand, S. P. Shah, O. M. Al-Agha et al., “ARID1A mutations in endometriosis-associated ovarian carcinomas,” New England Journal of Medicine, vol. 363, no. 16, pp. 1532–1543, 2010. View at Publisher · View at Google Scholar
  59. S. Jones, T.-L. Wang, I.-M. Shih et al., “Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma,” Science, vol. 330, no. 6001, pp. 228–231, 2010. View at Publisher · View at Google Scholar
  60. C. Balch, T. H. M. Huang, R. Brown, and K. P. Nephew, “The epigenetics of ovarian cancer drug resistance and resensitization,” American Journal of Obstetrics and Gynecology, vol. 191, no. 5, pp. 1552–1572, 2004. View at Publisher · View at Google Scholar · View at Scopus
  61. D. O. Bauerschlag, C. Schem, M. T. Weigel et al., “The role of p53 as a surrogate marker for chemotherapeutical responsiveness in ovarian cancer,” Journal of Cancer Research and Clinical Oncology, vol. 136, no. 1, pp. 79–88, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. S. A. Elg, L. F. Carson, J. M. Fowler, L. B. Twiggs, M. M. Moradi, and S. Ramakrishnan, “Ascites levels of haptoglobin in patients with ovarian cancer,” Cancer, vol. 71, no. 12, pp. 3938–3941, 1993. View at Google Scholar · View at Scopus
  63. W. Dobryszycka, J. Gerber, J. Zuwała-Jagiełło, and M. Ujec, “Acute phase reactants and circulating immune complexes in patients with ovarian carcinoma,” Archivum Immunologiae et Therapiae Experimentalis, vol. 39, no. 1-2, pp. 41–50, 1991. View at Google Scholar · View at Scopus
  64. G. Beckman, A. Eklund, N. Frohlander, and N. Sjernberg, “Haptoglobin groups and lung cancer,” Human Heredity, vol. 36, no. 4, pp. 258–260, 1986. View at Google Scholar · View at Scopus
  65. R. Epelbaum, C. Shalitin, R. Segal et al., “Haptoglobin-related protein as a serum marker in malignant lymphoma,” Pathology and Oncology Research, vol. 4, no. 4, pp. 271–276, 1998. View at Google Scholar · View at Scopus
  66. S. M. Awadallah and M. F. Atoum, “Haptoglobin polymorphism in breast cancer patients form Jordan,” Clinica Chimica Acta, vol. 341, no. 1-2, pp. 17–21, 2004. View at Publisher · View at Google Scholar · View at Scopus
  67. D. T. Denhardt and M. Noda, “Osteopontin expression and function: role in bone remodeling,” Journal of cellular biochemistry. Supplement, vol. 30-31, pp. 92–102, 1998. View at Google Scholar · View at Scopus
  68. K. A. Brakora, H. Lee, R. Yusuf et al., “Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer,” Gynecologic Oncology, vol. 93, no. 2, pp. 361–365, 2004. View at Publisher · View at Google Scholar · View at Scopus
  69. C. Kirchhoff, I. Habben, R. Iveli, and N. Krull, “A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors,” Biology of Reproduction, vol. 45, no. 2, pp. 350–357, 1991. View at Google Scholar · View at Scopus
  70. M. Schummer, W. V. Ng, R. E. Bumgarner et al., “Comparative hybridization of an array of 21 500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas,” Gene, vol. 238, no. 2, pp. 375–385, 1999. View at Publisher · View at Google Scholar · View at Scopus
  71. I. Hellstrom and K. E. Hellstrom, “SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other,” Advances in Experimental Medicine and Biology, vol. 622, pp. 15–21, 2008. View at Publisher · View at Google Scholar · View at Scopus
  72. I. Heliström, J. Raycraft, M. Hayden-Ledbetter et al., “The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma,” Cancer Research, vol. 63, no. 13, pp. 3695–3700, 2003. View at Google Scholar · View at Scopus
  73. S. Salceda, T. Tang, M. Kmet et al., “The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation,” Experimental Cell Research, vol. 306, no. 1, pp. 128–141, 2005. View at Publisher · View at Google Scholar · View at Scopus
  74. I. Simon, Y. Liu, K. L. Krall et al., “Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer,” Gynecologic Oncology, vol. 106, no. 1, pp. 112–118, 2007. View at Publisher · View at Google Scholar · View at Scopus
  75. B. M. Kacinski, E. R. Stanley, D. Carter et al., “Circulating levels of CSF-1 (M-CSF) a lymphohematopoietic cytokine may be a useful marker of disease status in patients with malignant ovarian neoplasms,” International Journal of Radiation Oncology Biology Physics, vol. 17, no. 1, pp. 159–164, 1989. View at Google Scholar · View at Scopus
  76. F. J. Xu, Y. H. Yu, L. Daly et al., “OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures,” Journal of Clinical Oncology, vol. 11, no. 8, pp. 1506–1510, 1993. View at Google Scholar · View at Scopus
  77. D. A. Hazelton and T. C. Hamilton, “Vascular endothelial growth factor in ovarian cancer,” Current oncology reports, vol. 1, no. 1, pp. 59–63, 1999. View at Google Scholar · View at Scopus
  78. A. Kraft, K. Weindel, A. Ochs et al., “Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease,” Cancer, vol. 85, no. 1, pp. 178–187, 1999. View at Publisher · View at Google Scholar · View at Scopus
  79. R. Sutphen, Y. Xu, G. D. Wilbanks et al., “Lysophospholipids are potential biomarkers of ovarian cancer,” Cancer Epidemiology Biomarkers and Prevention, vol. 13, no. 7, pp. 1185–1191, 2004. View at Google Scholar · View at Scopus
  80. B. Ye, S. Skates, S. C. Mok et al., “Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine,” Clinical Cancer Research, vol. 12, no. 2, pp. 432–441, 2006. View at Publisher · View at Google Scholar · View at Scopus
  81. K. Y. K. Chan, H. Ozçelik, A. N. Y. Cheung, H. Y. S. Ngan, and UI. S. Khoo, “Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer,” Cancer Research, vol. 62, no. 14, pp. 4151–4156, 2002. View at Google Scholar · View at Scopus
  82. G. Strathdee, K. Appleton, M. Illand et al., “Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes,” American Journal of Pathology, vol. 158, no. 3, pp. 1121–1127, 2001. View at Google Scholar · View at Scopus
  83. P. A. Futreal, Q. Liu, D. Shattuck-Eidens et al., “BRCA1 mutations in primary breast and ovarian carcinomas,” Science, vol. 266, no. 5182, pp. 120–122, 1994. View at Google Scholar · View at Scopus
  84. J. Z. Press, A. De Luca, N. Boyd et al., “Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities,” BMC Cancer, vol. 8, article no. 17, 2008. View at Publisher · View at Google Scholar · View at Scopus
  85. J. Yuan, R. Z. Luo, S. Fujii et al., “Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers,” Cancer Research, vol. 63, no. 14, pp. 4174–4180, 2003. View at Google Scholar · View at Scopus
  86. J. F. Costello and C. Plass, “Methylation matters,” Journal of Medical Genetics, vol. 38, no. 5, pp. 285–303, 2001. View at Google Scholar · View at Scopus
  87. Y. Yu, R. Luo, Z. Lu et al., “Biochemistry and biology of ARHI (DIRAS3), an imprinted tumor suppressor gene whose expression is lost in ovarian and breast cancers,” Methods in Enzymology, vol. 407, pp. 455–468, 2006. View at Publisher · View at Google Scholar · View at Scopus
  88. D. G. Rosen, L. Wang, A. N. Jain et al., “Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21 and prolonged progression-free survival,” Clinical Cancer Research, vol. 10, no. 19, pp. 6559–6566, 2004. View at Publisher · View at Google Scholar · View at Scopus
  89. A. Czekierdowski, S. Czekierdowska, M. Szymanski, M. Wielgos, P. Kaminski, and J. Kotarski, “Opioid-binding protein/cell adhesion molecule-like (OPCML) gene and promoter methylation status in women with ovarian cancer,” Neuroendocrinology Letters, vol. 27, no. 5, pp. 609–613, 2006. View at Google Scholar · View at Scopus
  90. J. H. Yoon, R. Dammann, and G. P. Pfeifer, “Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas,” International Journal of Cancer, vol. 94, no. 2, pp. 212–217, 2001. View at Publisher · View at Google Scholar · View at Scopus
  91. H. Yu and T. Rohan, “Role of the insulin-like growth factor family in cancer development and progression,” Journal of the National Cancer Institute, vol. 92, no. 18, pp. 1472–1489, 2000. View at Google Scholar · View at Scopus
  92. A. Flyvbjerg, O. Mogensen, B. Mogensen, and O. S. Nielsen, “Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: correlation with cancer antigen 125 and tumor-associated trypsin inhibitor,” Journal of Clinical Endocrinology and Metabolism, vol. 82, no. 7, pp. 2308–2313, 1997. View at Publisher · View at Google Scholar · View at Scopus
  93. J. I. Akahira, Y. Sugihashi, T. Suzuki et al., “Decreased expression of 14-3-3σ is associated with advanced disease in human epithelial ovarian cancer: its correlation with aberrant DNA methylation,” Clinical Cancer Research, vol. 10, no. 8, pp. 2687–2693, 2004. View at Publisher · View at Google Scholar · View at Scopus
  94. G. Z. Qu, L. Dubeau, A. Narayan, M. C. Yu, and M. Ehrlich, “Satellite DNA hypomethylation vs. overall genomic hypomethylation in ovarian epithelial tumors of different malignant potential,” Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol. 423, no. 1-2, pp. 91–101, 1999. View at Publisher · View at Google Scholar · View at Scopus
  95. V. Shridhar, K. C. Bible, J. Staub et al., “Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer,” Cancer Research, vol. 61, no. 10, pp. 4258–4265, 2001. View at Google Scholar · View at Scopus
  96. J. M. Lancaster, H. K. Dressman, J. P. Clarke et al., “Identification of genes associated with ovarian cancer metastasis using microarray expression analysis,” International Journal of Gynecological Cancer, vol. 16, no. 5, pp. 1733–1745, 2006. View at Publisher · View at Google Scholar · View at Scopus
  97. B. J. Milner, L. A. Allan, D. M. Eccles et al., “p53 mutation is a common genetic event in ovarian carcinoma,” Cancer Research, vol. 53, no. 9, pp. 2128–2132, 1993. View at Google Scholar · View at Scopus
  98. R. Tuma, “Targeted epigenetic therapies: the next frontier?” Journal of the National Cancer Institute, vol. 102, no. 24, pp. 1824–1825, 2010. View at Google Scholar
  99. N. E. Tchabo, M. S. Liel, and E. C. Kohn, “Applying proteomics in clinical trials: assessing the potential and practical limitations in ovarian cancer,” American Journal of PharmacoGenomics, vol. 5, no. 3, pp. 141–148, 2005. View at Publisher · View at Google Scholar · View at Scopus
  100. J. L. Hays, G. Kim, I. Giuroiu, and E. C. Kohn, “Proteomics and ovarian cancer: integrating proteomics information into clinical care,” Journal of Proteomics, vol. 73, no. 10, pp. 1864–1872, 2010. View at Publisher · View at Google Scholar · View at Scopus
  101. R. S. Tirumalai, K. C. Chan, D. A. Prieto, H. J. Issaq, T. P. Conrads, and T. D. Veenstra, “Characterization of the low molecular weight human serum proteome,” Molecular & Cellular Proteomics, vol. 2, no. 10, pp. 1096–1103, 2003. View at Google Scholar · View at Scopus
  102. M. F. Lopez, A. Mikulskis, S. Kuzdzal et al., “A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples,” Clinical Chemistry, vol. 53, no. 6, pp. 1067–1074, 2007. View at Publisher · View at Google Scholar · View at Scopus
  103. Y. J. Hong, X. D. Wang, D. Shen, and SU. Zeng, “Discrimination analysis of mass spectrometry proteomics for ovarian cancer detection,” Acta Pharmacologica Sinica, vol. 29, no. 10, pp. 1240–1246, 2008. View at Publisher · View at Google Scholar · View at Scopus
  104. J. Wang, X. Zhang, X. Ge, H. Guo, G. Xiong, and Y. Zhu, “Proteomic studies of early-stage and advanced ovarian cancer patients,” Gynecologic Oncology, vol. 111, no. 1, pp. 111–119, 2008. View at Publisher · View at Google Scholar · View at Scopus
  105. T. Van Gorp, I. Cadron, and I. Vergote, “The utility of proteomics in gynecologic cancers,” Current Opinion in Obstetrics and Gynecology, vol. 23, no. 1, pp. 3–7, 2011. View at Publisher · View at Google Scholar
  106. R. C. Bast Jr., D. Badgwell, Z. Lu et al., “New tumor markers: CA125 and beyond,” International Journal of Gynecological Cancer, vol. 15, no. 6, supplement 3, pp. 274–281, 2005. View at Google Scholar
  107. I. Visintin, Z. Feng, G. Longton et al., “Diagnostic markers for early detection of ovarian cancer,” Clinical Cancer Research, vol. 14, no. 4, pp. 1065–1072, 2008. View at Publisher · View at Google Scholar · View at Scopus
  108. V. Nosov, F. Su, M. Amneus et al., “Validation of serum biomarkers for detection of early-stage ovarian cancer,” American Journal of Obstetrics and Gynecology, vol. 200, no. 6, pp. 639.e1–639.e5, 2009. View at Publisher · View at Google Scholar · View at Scopus
  109. S. D. Amonkar, G. P. Bertenshaw, T. H. Chen et al., “Development and preliminary evaluation of a multivariate index assay for ovarian cancer,” PLoS One, vol. 4, no. 2, Article ID e4599, 2009. View at Publisher · View at Google Scholar · View at Scopus
  110. C. Balch, J. S. Montgomery, H. I. Paik, S. Kim, T. H. M. Huang, and K. P. Nephew, “New anti-cancer strategies: epigenetic therapies and biomarkers,” Frontiers in Bioscience, vol. 10, no. 2, pp. 1897–1931, 2005. View at Google Scholar · View at Scopus
  111. A. Melnikov, D. Scholtens, A. Godwin, and V. Levenson, “Differential methylation profile of ovarian cancer in tissues and plasma,” Journal of Molecular Diagnostics, vol. 11, no. 1, pp. 60–65, 2009. View at Publisher · View at Google Scholar · View at Scopus
  112. S. H. Wei, C. Balch, H. H. Paik et al., “Prognostic DNA methylation biomarkers in ovarian cancer,” Clinical Cancer Research, vol. 12, no. 9, pp. 2788–2794, 2006. View at Publisher · View at Google Scholar · View at Scopus
  113. U.S. Food and Drug Administration, “FDA news release: FDA clears a test for ovarian cancer,” January 2011, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm182057.htm.
  114. C. Y. Muller, “Doctor, should I get this new ovarian cancer test-OVA1?” Obstetrics and Gynecology, vol. 116, no. 2, part 1, pp. 246–247, 2010. View at Publisher · View at Google Scholar
  115. D. Stirling, D. G. R. Evans, G. Pichert et al., “Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the International Federation of Gynecology and Obstetrics System,” Journal of Clinical Oncology, vol. 23, no. 24, pp. 5589–5596, 2005. View at Publisher · View at Google Scholar · View at Scopus
  116. R. I. Olivier, M. A. C. Lubsen-Brandsma, S. Verhoef, and M. Van Beurden, “CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer,” Gynecologic Oncology, vol. 100, no. 1, pp. 20–26, 2006. View at Publisher · View at Google Scholar · View at Scopus
  117. E. R. Woodward, H. V. Sleightholme, A. M. Considine, S. Williamson, J. M. McHugo, and D. G. Cruger, “Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective,” BJOG, vol. 114, no. 12, pp. 1500–1509, 2007. View at Publisher · View at Google Scholar · View at Scopus